Biotechnology

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...

2024-03-06 08:30 3180

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...

2024-03-06 05:30 2820

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A ( PureRec RNase A), a challenge that persisted for over half a century. This breakthroug...

2024-03-05 22:00 2204

Angel Yeast Hosts Webinar with PPTI to Promote Sustainable Development of Proteins

SHANGHAI, March 5, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, recently successfully hosted a webinar event with Protein Production Technology International (PPTI), a digital publication dedicated to the alternative proteins sp...

2024-03-05 21:00 4326

IRBM Expands Global Reach in Drug Discovery with New Boston Office

Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...

2024-03-05 20:24 3305

First Patient Treated in Phase 2 GvHD Trial

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...

2024-03-05 10:08 2960

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...

2024-03-04 21:19 3791

Hybribio Calls for Raising International HPV Awareness

GUANGZHOU, China, March 4, 2024 /PRNewswire/ -- March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raisi...

2024-03-04 18:47 3699

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...

2024-03-04 16:53 2822

Thermo Fisher Scientific to Inaugurate New Office, Marking Milestone Expansion in Indonesia

Company to support advancements in country's science and technology sector, with a focus on progressing healthcare, environmental solutions, and food safety JAKARTA, Indonesia, March. 1, 2024 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, will significantly expand ...

2024-03-01 10:30 11147

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2024-03-01 08:00 4883

Metabolon Unveils New Integrated Bioinformatics Platform

Metabolon's cutting-edge bioinformatics platform and unique knowledge base will enable customers to leverage the company's extensive biochemistry experience MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide var...

2024-02-29 20:58 2330

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to ...

2024-02-29 17:40 2519

MGI Tech & Juntendo University: Changing the Landscape and Unlocking Answers for Patients with Rare Diseases

TOKYO, Feb. 29, 2024 /PRNewswire/ -- Rare diseases have historically been overlooked because they affect relatively few people. While they are identified and addressed differently around the world, there are over known 6,000 rare diseases – characterized by a wide range of disorders and symptoms...

2024-02-29 09:00 3587

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological ...

2024-02-28 21:32 2162

RRD International is now RRD Biopharma Development

RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model. ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launch...

2024-02-28 21:00 3140

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide in...

2024-02-28 02:30 1994

New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks

TOKYO, Feb. 27, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, have obtained CE marks for new models of PENTAX Medical i20c Video Endoscope Series - PENTAX Medical Video Colonoscope EC34-i20c, PENTAX Medical Video Upper GI Scope EG27-i20c and R/L Knob Adaptor OE-B17.

2024-02-27 17:00 2481

Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...

2024-02-27 16:09 2743

Sengenics Corporation Announces Key Distributor in China

Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services inChina BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has enter...

2024-02-27 08:30 3159
1 ... 74757677787980 ... 184